首页 | 本学科首页   官方微博 | 高级检索  
     


Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus
Authors:Horák P  Scudla V  Hermanovó Z  Pospisil Z  Faltýnek L  Budiková M  Kusá L
Affiliation:(1) Third Department of Internal Medicine, CZ;(2) Department of Clinical Immunology, CZ;(3) Department of Nuclear Medicine, University Hospital of Olomouc, Olomouc, Czech Republic, CZ
Abstract:The objective of this study was to assess the utility of measurement of thrombomodulin, antinucleosome antibodies, sVCAM-1, sICAM-1, neopterin, fas ligand, IL-10 and sIL-2R in patients with systemic lupus erythematosus (SLE) and to compare them with traditional markers of SLE activity (anti-dsDNA antibodies, C3, C4) and the ECLAM index of disease activity. The measurement was performed over a 6-month period at three consecutive time points after 3 months in each of the 52 patients with SLE. Anti-dsDNA antibodies, thrombomodulin, antinucleosome antibodies, sVCAM-1m sICAM-1, neopterin, fas ligand, IL-10 and sIL-2R were tested by ELISA technique, while C3, C4 components of complement were tested by nephelometry. Fas ligand and IL-10 did not correlate with the ECLAM index. The rest of the markers showed significant correlation with the disease activity index. Thrombomodulin and anti-dsDNA antibodies reflect in the best way the changing trend in disease activity. Antinucleosome antibodies seem to be a promising marker useful in early diagnosis. Soluble VCAM-1, sICAM-1, neopterin and sIL-2R are interesting molecules with a role in disease pathogenesis, but their practical utility is limited. Received: 27 September 2000 / Accepted: 31 March 2001
Keywords::Adhesive molecules –   Antibodies –   Cytokines –   Disease activity –   Neopterin –   Systemic lupus erythematosus –   Thrombomodulin
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号